UB Paderborn / Katalog / Suche / in CDI

The incidence and magnitude of fibrinolytic activation in trauma patients

Journal of thrombosis and haemostasis, 2013-02, Vol.11 (2), p.307-314

2013

Link zum Volltext

Verfügbarkeit prüfen

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.487-498

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

The New England journal of medicine, 2017-08, Vol.377 (9), p.819-828

2017

Link zum Volltext

Verfügbarkeit prüfen

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.697-704

2017

Link zum Volltext

Verfügbarkeit prüfen

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Journal of thrombosis and haemostasis, 2014-11, Vol.12 (11), p.1788-1800

2014

Link zum Volltext

Verfügbarkeit prüfen

Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis

Journal of thrombosis and haemostasis, 2016-11, Vol.14 (11), p.2141-2147

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.72-80

2016

Link zum Volltext

Verfügbarkeit prüfen

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-05, Vol.10 (3), p.218-231

2004

Link zum Volltext

Verfügbarkeit prüfen

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-05, Vol.10 (3), p.199-217

2004

Link zum Volltext

Verfügbarkeit prüfen

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.490-495

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-11, Vol.20 (6), p.846-853

2014

Link zum Volltext

Verfügbarkeit prüfen

Access to primary dental care for patients with inherited bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (4), p.510-515

2012

Link zum Volltext

Verfügbarkeit prüfen

Fatal postoperative pulmonary embolism in mild haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2006-03, Vol.12 (2), p.179-182

2006

Link zum Volltext

Verfügbarkeit prüfen

Thrombotic risk factors associated with transurethral prostatectomy

BJU international, 1999-06, Vol.83 (9), p.984-989

1999

Link zum Volltext

Verfügbarkeit prüfen

Type 1 von Willebrand disease — a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history

British journal of haematology, 2000-02, Vol.108 (2), p.259-264

2000

Link zum Volltext

Verfügbarkeit prüfen

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

The New England journal of medicine, 2022-03, Vol.386 (11), p.1013-1025

2022

Link zum Volltext

Verfügbarkeit prüfen

von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use

Thrombosis and haemostasis, 1997-10, Vol.78 (4), p.1272

1997

Link zum Volltext

Verfügbarkeit prüfen

Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling

Thrombosis and haemostasis, 2000-12, Vol.84 (6), p.998

2000

Link zum Volltext

Verfügbarkeit prüfen

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

British journal of haematology, 1996-05, Vol.93 (2), p.457-459

1996

Link zum Volltext

Verfügbarkeit prüfen

Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor

Thrombosis and haemostasis, 2000-08, Vol.84 (2), p.188

2000

Link zum Volltext

Verfügbarkeit prüfen

A framework for genetic service provision for haemophilia and other inherited bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2005-03, Vol.11 (2), p.145-163

2005

Link zum Volltext

Verfügbarkeit prüfen

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period

Clinical and laboratory haematology, 2000-10, Vol.22 (5), p.275-278

2000

Link zum Volltext

Verfügbarkeit prüfen

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

Haemophilia : the official journal of the World Federation of Hemophilia, 2002-03, Vol.8 (2), p.91-97

2002

Link zum Volltext

Verfügbarkeit prüfen

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product

Thrombosis and haemostasis, 1997-09, Vol.78 (3), p.1027

1997

Link zum Volltext

Verfügbarkeit prüfen

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

British journal of haematology, 1999-03, Vol.104 (4), p.909-914

1999

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The incidence and magnitude of fibrinolytic activation in trauma patients

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience

Access to primary dental care for patients with inherited bleeding disorders

Fatal postoperative pulmonary embolism in mild haemophilia

Thrombotic risk factors associated with transurethral prostatectomy

Type 1 von Willebrand disease — a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use

Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor

A framework for genetic service provision for haemophilia and other inherited bleeding disorders

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

Suchergebnisse filtern